Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone858-550-7500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$251.45 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions
What is Ligand Pharmaceuticals' stock symbol?
Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."
How were Ligand Pharmaceuticals' earnings last quarter?
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announced its earnings results on Thursday, February, 7th. The biotechnology company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.48. The biotechnology company earned $59.59 million during the quarter, compared to the consensus estimate of $52.58 million. Ligand Pharmaceuticals had a net margin of 57.00% and a return on equity of 26.00%. The business's quarterly revenue was up 18.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.31 earnings per share. View Ligand Pharmaceuticals' Earnings History.
When is Ligand Pharmaceuticals' next earnings date?
What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?
Ligand Pharmaceuticals issued an update on its FY19 earnings guidance on Thursday, February, 7th. The company provided EPS guidance of ~$6.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.53. The company issued revenue guidance of ~$224 million, compared to the consensus revenue estimate of $213.42 million.Ligand Pharmaceuticals also updated its FY 2019 guidance to $6.05-6.05 EPS.
What price target have analysts set for LGND?
6 brokerages have issued 12 month price objectives for Ligand Pharmaceuticals' shares. Their predictions range from $150.00 to $260.00. On average, they expect Ligand Pharmaceuticals' share price to reach $224.6667 in the next year. This suggests a possible upside of 84.0% from the stock's current price. View Analyst Price Targets for Ligand Pharmaceuticals.
What is the consensus analysts' recommendation for Ligand Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ligand Pharmaceuticals.
What are Wall Street analysts saying about Ligand Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Ligand reported encouraging fourth-quarter results, beating estimates on both counts. The company’s Captisol Formulation technology resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Ligand is acquiring other technology platforms like OmniAb platform from OMT acquisition to reduce dependence on Captisol formulation. OmniAb is likely to drive future revenues. Shares of Ligand have underperformed the industry so far this year. Following the sale Promacta rights, the company will derive a substantial portion of its revenues from royalties associated with the sales of Kyprolis. The drug has shown encouraging growth and will achieve blockbuster status in 2019. However, any setback related to this product could have a substantial impact." (3/27/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $254 price target. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 200 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales, and collaborative revenue." (3/13/2019)
Has Ligand Pharmaceuticals been receiving favorable news coverage?
Media headlines about LGND stock have trended very positive on Friday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ligand Pharmaceuticals earned a media sentiment score of 3.6 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Ligand Pharmaceuticals' key competitors?
Some companies that are related to Ligand Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Marina Biotech (MRNA), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), Beigene (BGNE), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Amarin (AMRN), Nektar Therapeutics (NKTR) and Alkermes (ALKS).
What other stocks do shareholders of Ligand Pharmaceuticals own?
Who are Ligand Pharmaceuticals' key executives?
Ligand Pharmaceuticals' management team includes the folowing people:
- Mr. John L. Higgins, CEO & Exec. Director (Age 49)
- Mr. Matthew W. Foehr, Pres & COO (Age 46)
- Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 44)
- Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 50)
- Mr. Todd Pettingill, Director of Corp. Devel.
Who are Ligand Pharmaceuticals' major shareholders?
Ligand Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Conestoga Capital Advisors LLC (3.04%), Woodstock Corp (0.35%), Summit Creek Advisors LLC (0.23%), Retirement Systems of Alabama (0.13%), Louisiana State Employees Retirement System (0.03%) and Harvest Investment Services LLC (0.03%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.
Which institutional investors are selling Ligand Pharmaceuticals stock?
LGND stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Retirement Systems of Alabama, Louisiana State Employees Retirement System and Summit Creek Advisors LLC. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr and Todd C Davis. View Insider Buying and Selling for Ligand Pharmaceuticals.
Which institutional investors are buying Ligand Pharmaceuticals stock?
LGND stock was bought by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, Harvest Investment Services LLC, Eqis Capital Management Inc., Virtu Financial LLC and Woodstock Corp. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh and John L Higgins. View Insider Buying and Selling for Ligand Pharmaceuticals.
How do I buy shares of Ligand Pharmaceuticals?
Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ligand Pharmaceuticals' stock price today?
One share of LGND stock can currently be purchased for approximately $122.11.
How big of a company is Ligand Pharmaceuticals?
Ligand Pharmaceuticals has a market capitalization of $2.50 billion and generates $251.45 million in revenue each year. The biotechnology company earns $143.32 million in net income (profit) each year or $6.28 on an earnings per share basis.
What is Ligand Pharmaceuticals' official website?
How can I contact Ligand Pharmaceuticals?
Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]
MarketBeat Community Rating for Ligand Pharmaceuticals (NASDAQ LGND)
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days.
